Handelsbanken Fonder AB bought a new stake in shares of STAAR Surgical (NASDAQ:STAA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 7,600 shares of the medical instruments supplier’s stock, valued at approximately $468,000.

Several other large investors have also made changes to their positions in the company. BNP Paribas Arbitrage SA lifted its holdings in STAAR Surgical by 488.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 33,812 shares of the medical instruments supplier’s stock valued at $1,091,000 after purchasing an additional 28,068 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in STAAR Surgical by 106.6% in the 2nd quarter. Mutual of America Capital Management LLC now owns 79,719 shares of the medical instruments supplier’s stock valued at $4,906,000 after purchasing an additional 41,134 shares in the last quarter. Dupont Capital Management Corp purchased a new position in STAAR Surgical in the 2nd quarter valued at $601,000. Legal & General Group Plc lifted its holdings in STAAR Surgical by 19.3% in the 1st quarter. Legal & General Group Plc now owns 18,068 shares of the medical instruments supplier’s stock valued at $595,000 after purchasing an additional 2,921 shares in the last quarter. Finally, Advisor Group Holdings Inc. purchased a new position in STAAR Surgical in the 1st quarter valued at $1,146,000. Hedge funds and other institutional investors own 90.18% of the company’s stock.

A number of brokerages have weighed in on STAA. Benchmark raised their price objective on STAAR Surgical from $50.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Sidoti upgraded STAAR Surgical from a “neutral” rating to a “buy” rating and set a $58.00 price target on the stock in a report on Monday, August 31st. Canaccord Genuity lifted their price target on STAAR Surgical from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. BidaskClub upgraded STAAR Surgical from a “sell” rating to a “hold” rating in a report on Saturday, September 5th. Finally, Zacks Investment Research upgraded STAAR Surgical from a “sell” rating to a “hold” rating in a report on Tuesday, August 18th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $55.71.

In other news, CTO Keith Holliday sold 35,689 shares of STAAR Surgical stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $53.32, for a total value of $1,902,937.48. Following the completion of the transaction, the chief technology officer now owns 29,733 shares in the company, valued at approximately $1,585,363.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jon K. Hayashida sold 41,602 shares of STAAR Surgical stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $51.22, for a total value of $2,130,854.44. Following the completion of the transaction, the vice president now owns 27,000 shares of the company’s stock, valued at approximately $1,382,940. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.

NASDAQ STAA opened at $55.10 on Monday. The company has a market cap of $2.52 billion, a P/E ratio of 344.40 and a beta of 1.43. The stock has a 50-day moving average of $50.56 and a two-hundred day moving average of $44.77. STAAR Surgical has a 1-year low of $23.20 and a 1-year high of $62.51.

STAAR Surgical (NASDAQ:STAA) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). The firm had revenue of $35.19 million during the quarter, compared to analyst estimates of $37.60 million. STAAR Surgical had a net margin of 5.03% and a return on equity of 8.78%. During the same period in the prior year, the firm earned $0.08 earnings per share. On average, sell-side analysts anticipate that STAAR Surgical will post 0.15 EPS for the current fiscal year.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Recommended Story: Options Trading

Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA).

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.